Journal of endocrinological investigation · 2026
Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sagan Karol P, Lipiec-Rzepecka Zuzanna, Patalong-Wójcik Martyna, Wasilewicz Michał P, Andrysiak-Mamos Elżbieta, Syrenicz Anhelli
Аннотация
PURPOSE: Excess growth hormone, as encountered in acromegaly, promotes insulin resistance and enhances adipose tissue lipolysis. This study aimed to summarize the currently available data on the prevalence of hepatic steatosis and liver fibrosis in patients with acromegaly. The secondary objective was to map the studies on the influence of treatment modalities on hepatic outcomes in this population.
METHODS: This scoping review was conducted following the PRISMA-ScR guidelines. We performed a systematic literature search across two electronic databases: PubMed and Web of Science from their inception to the 4th of April 2026. In addition, articles were identified through manual searches using Google Scholar and citation tracking. Peer-reviewed original journal articles evaluating hepatic steatosis, fibrosis, and intracellular hepatic lipid (IHL) content in patients with acromegaly were included. Studies that did not utilize radiological methods and case reports were excluded. Results were synthesized narratively and summarized in tables.
RESULTS: Twenty-one original studies were included. High heterogeneity was observed among the studies, including study models, imaging methods, patient populations, and outcomes. The data presented in this literature review reveal a pattern of lower IHL content in active acromegaly patients but a higher likelihood of liver fibrosis compared with controls. Control of acromegaly may be associated with a rise in IHL content.
CONCLUSIONS: IHL content and hepatic fibrosis in patients with acromegaly may be influenced by disease control status and treatment modalities. Further high-quality studies are required to assess the risk of liver steatosis and fibrosis in this patient population.
METHODS: This scoping review was conducted following the PRISMA-ScR guidelines. We performed a systematic literature search across two electronic databases: PubMed and Web of Science from their inception to the 4th of April 2026. In addition, articles were identified through manual searches using Google Scholar and citation tracking. Peer-reviewed original journal articles evaluating hepatic steatosis, fibrosis, and intracellular hepatic lipid (IHL) content in patients with acromegaly were included. Studies that did not utilize radiological methods and case reports were excluded. Results were synthesized narratively and summarized in tables.
RESULTS: Twenty-one original studies were included. High heterogeneity was observed among the studies, including study models, imaging methods, patient populations, and outcomes. The data presented in this literature review reveal a pattern of lower IHL content in active acromegaly patients but a higher likelihood of liver fibrosis compared with controls. Control of acromegaly may be associated with a rise in IHL content.
CONCLUSIONS: IHL content and hepatic fibrosis in patients with acromegaly may be influenced by disease control status and treatment modalities. Further high-quality studies are required to assess the risk of liver steatosis and fibrosis in this patient population.